|
Market Closed -
Euronext Paris
03:55:00 21/11/26 am AEDT
|
5-day change | 1st Jan Change | ||
| 0.8280 EUR | -8.51% |
|
-31.00% | -48.31% |
| 19/11 | Leerink Partners Downgrades Innate Pharma to Market Perform From Outperform, Price Target is $1 | MT |
| 19/11 | Innate Pharma S.A. - Special Call |
| Market Cap | 77.58M 85.18M 71.49M 65.03M 122M 7.89B 128M 870M 346M 4.31B 320M 313M 13.52B | P/E 2026 * |
7.06x | P/E 2027 * | 0.91x |
|---|---|---|---|---|---|
| Enterprise Value | 22.58M 24.8M 20.81M 18.93M 35.51M 2.3B 37.32M 253M 101M 1.25B 93.03M 91.07M 3.94B | EV / Sales 2026 * |
0.48x | EV / Sales 2027 * | -0.86x |
| Free-Float |
98.16% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Euronext Paris
| IPH | Real-time | |
| IPHp | Real-time | ||
| IDD | Delayed | ||
| IDD | Real-time | ||
| IDD | Delayed | ||
| IPHYF | Delayed | ||
| IDD | Real-time | ||
| IDD | Delayed | ||
| 0EVI | Delayed | ||
| 0EVI | Real-time | ||
| 4IPH | End-of-day quote |
Last Transcript: Innate Pharma
| 1 day | -8.51% | ||
| 1 week | -31.00% | ||
| Current month | -34.08% | ||
| 1 month | -38.67% | ||
| 3 months | -53.48% | ||
| 6 months | -57.76% | ||
| Current year | -48.31% |
| 1 week | 0.81 | 1.29 | |
| 1 month | 0.81 | 1.42 | |
| Current year | 0.81 | 2.33 | |
| 1 year | 0.81 | 2.33 | |
| 3 years | 0.81 | 2.8 | |
| 5 years | 0.81 | 4.84 | |
| 10 years | 0.81 | 15.83 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 01/11/2024 | |
Frederic Lombard
DFI | Director of Finance/CFO | 51 | 01/04/2021 |
Markus Jensen
CTO | Chief Tech/Sci/R&D Officer | 57 | 01/09/2026 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 66 | 01/01/2024 | |
| Director/Board Member | 65 | 27/04/2015 | |
Pascale Boissel
BRD | Director/Board Member | 60 | 19/05/2020 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 14/8/26 | BPIFrance Participations SA /PRIVATE EQUITY/
| Buy | Company | 1,764,705 | 1.8789% | |
| 20/1/26 | Buy | Executive/Senior Manager | 50,000 | 0.0542% | ||
| 16/1/26 | Buy | Chief Financial Officer | 50,000 | 0.0542% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -8.51% | -31.00% | -48.38% | -64.69% | 85.18M | ||
| -2.49% | -3.76% | +50.31% | +62.10% | 63.66B | ||
| -0.63% | -2.91% | +6.20% | +89.22% | 58.56B | ||
| -2.37% | -2.22% | +22.87% | +82.31% | 54.19B | ||
| -2.19% | -6.15% | +11.92% | +108.08% | 44.66B | ||
| -1.89% | -7.28% | +13.22% | +19.74% | 40.51B | ||
| -0.93% | -0.47% | +19.73% | +43.75% | 36.27B | ||
| +1.11% | -6.44% | +130.68% | +641.83% | 34.89B | ||
| -0.80% | +0.61% | +77.26% | +56.26% | 32.26B | ||
| -2.17% | +16.65% | -29.21% | +474.05% | 31.01B | ||
| Average | -2.09% | -4.19% | +25.46% | +151.26% | 40B | |
| Weighted average by Cap. | -1.48% | -1.86% | +32.14% | +150.85% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 47.42M 52.06M 43.69M 39.75M 74.57M 4.82B 78.37M 532M 211M 2.63B 195M 191M 8.26B | 90M 98.81M 82.93M 75.43M 142M 9.15B 149M 1.01B 401M 5B 371M 363M 15.68B |
| Net income | -859K -943K -792K -720K -1.35M -87.33M -1.42M -9.63M -3.83M -47.7M -3.54M -3.46M -150M | 12.46M 13.68M 11.48M 10.45M 19.6M 1.27B 20.6M 140M 55.55M 692M 51.34M 50.26M 2.17B |
| Net Debt | -55M -60.39M -50.68M -46.1M -86.48M -5.59B -90.89M -617M -245M -3.05B -227M -222M -9.59B | -155M -170M -143M -130M -244M -15.77B -256M -1.74B -691M -8.61B -639M -625M -27.03B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 20/11/26 | EUR 0.8280 | -8.51% | 1,245,224 |
| 19/11/26 | EUR 0.9050 | -8.40% | 1,577,232 |
| 18/11/26 | EUR 0.9880 | -18.08% | 1,895,904 |
| 17/11/26 | EUR 1.206 | -2.43% | 393,886 |
| 16/11/26 | EUR 1.236 | +3.00% | 478,469 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- IPH Stock
Select your edition
All financial news and data tailored to specific country editions

















